Novo Nordisk cut ties with Hims & Hers, accusing the telehealth firm of promoting Wegovy copycat versions of the weight-loss ...

A separate Prime analysis, however, of year-over-year claims data for Wegovy and Zepbound only found an improvement in ...

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

India's drug regulator on Thursday approved the launch of pre-filled injector pens of Eli Lilly's blockbuster weight-loss drug, Mounjaro, giving the company more options to compete with rival Novo ...

Uninsured or self-pay obesity patients can get any dose of Wegovy for $299 from July 1–31, 2025. Patients can get their ...

Novo Nordisk continues to expand its partnerships with telehealth companies to broaden access to its blockbuster weight loss ...

Erectile dysfunction and anti-anxiety medication were among the most common illegal pharmaceuticals seized by Interpol in a ...

A new expert consensus statement issued by the American College of Cardiology said that cardiologists should “embrace” new weight-loss medications for patients with obesity, TCTMD reported June 25.

Gov. Jeff Landry vetoes a plan to cover costly weight-loss drugs for Louisiana state workers and teachers, citing long-term ...

Over 100 cases of acute pancreatitis have been reported to UK health regulators this year, many tied to the newest GLP-1 drug on the market.

Novo Nordisk says the decision was made based on “Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.” ...

For high-risk patients with type 2 diabetes, oral semaglutide reduced risk for major cardiovascular and ischemic limb-related ...